Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CHRM1CHRM2CHRM3CHRM4CHRM5
The experimentally established mechanism targets of Terodiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.96 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.96 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.96 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.96 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.96 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 4/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.96 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terodiline SCHEMBL78908 | 0.98 | HRH1 (1.00) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL9008621 | 0.98 | HRH1 (1.00) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL8149719 | 0.96 | HRH1 (0.89) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL579993 | 0.96 | HRH1 (0.96) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL110026 | 0.94 | HRH1 (0.93) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008867 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9107533 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008606 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9108716 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008774 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001450-B1 | DIRECTLY COMPRESSIBLE COMPOSITE FOR ORALLY DISINTEGRATING TABLETS | RUBICON RES PRIVATE LIMITED (IN) | 2019-01-30 | — | — | EP | claimed |
| CN-105550715-A | Integrated classifier construction method based on neighbor propagation clustering | UNIV DALIAN TECH | 2016-05-04 | — | — | CN | claimed |
| CN-101460150-B | Directly compressible compound for orally disintegrating tablets | RUBICON RES PRIVATE LTD | 2014-02-12 | — | — | CN | claimed |
| US-20090208576-A1 | Orally Disintegrating Tablets | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2009-08-20 | — | — | US | claimed |
| CN-101460150-A | Directly compressible compound for orally disintegrating tablets | RUBICON RES PRIVATE LTD (IN) | 2009-06-17 | — | — | CN | claimed |
| EP-2001450-A2 | DIRECTLY COMPRESSIBLE COMPOSITE FOR ORALLY DISINTEGRATING TABLETS | Rubicon Research Private Limited (IN) | 2008-12-17 | — | — | EP | claimed |
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007113856-A2 | DIRECTLY COMPRESSIBLE COMPOSITE FOR ORALLY DISINTEGRATING TABLETS | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2007-10-11 | — | — | WO | claimed |
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2007072503-A2 | COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS | PANACEA BIOTEC LTD. (IN) | 2007-06-28 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| JP-2002520437-A | — | — | 2002-07-09 | — | — | JP | claimed |
| CN-1315945-A | Nitrate salts of antihypertensive drugs | NICOX SA (FR) | 2001-10-03 | — | — | CN | claimed |
| CN-1308650-A | Method of coating pre-primed polyolefin films | HOECHST TRESPAPHAN GMBH (DE) | 2001-08-15 | — | — | CN | claimed |
| EP-1102806-A1 | METHOD OF COATING PRE-PRIMED POLYOLEFIN FILMS | Hoechst Trespaphan GmbH (DE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000002956-A1 | METHOD OF COATING PRE-PRIMED POLYOLEFIN FILMS | HOECHST TRESPAPHAN GMBH (DE) | 2000-01-20 | — | — | WO | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5010671-A | Flip chart pad | DENNISON STATIONERY PRODUCTS COMPANY (US) | 1991-04-30 | — | — | US | claimed |